Novel targets for ATM-deficient malignancies.
Conventional chemo- and radiotherapies for the treatment of cancer target rapidly dividing cells in both tumor and non-tumor tissues and can exhibit severe cytotoxicity in normal tissue and impair the patient's immune system. Novel targeted strategies aim for higher efficacy and tumor specificity. The role of ATM protein in the DNA damage response is well known and ATM deficiency frequently plays a role in tumorigenesis and development of malignancy. In addition to contributing to disease development, ATM deficiency also renders malignant cells heavily dependent on other pathways that cooperate with the ATM-mediated DNA damage response to ensure tumor cell survival. Disturbing those cooperative pathways by inhibiting critical protein components allows specific targeting of tumors while sparing healthy cells with normal ATM status. We review druggable candidate targets for the treatment of ATM-deficient malignancies and the mechanisms underlying such targeted therapies.
Institute for Genetics; University of Cologne; Cologne, Germany.
Johannes
J
Winkler
Institute for Genetics; University of Cologne; Cologne, Germany.
Kay
K
Hofmann
Institute for Genetics; University of Cologne; Cologne, Germany.
Shuhua
S
Chen
ATM; DNA damage response; Homologous recombination; personalized therapy; synthetic lethality